International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135



Research Article

Innovations in Nanotechnology-Enhanced Proniosomal Systems for Targeted Drug Delivery

Submission Date: March 03, 2025, **Accepted Date:** April 02, 2025,
Published Date: May 01, 2025

Journal Website: http://sciencebring.com/index.php/ijasr

Dr. Maria S. Gonzalez
Department of Nanotechnology, University of Barcelona, Spain

Dr. Javid K. Malik
Department of Drug Delivery Systems, University of Toronto, Canada

Abstract

Proniosomes are a promising drug delivery system, and their integration with nanotechnology offers significant advantages. This article reviews the current state of nanotechnology integration in proniosomal drug delivery systems, highlighting the benefits, challenges, and future directions of this combined approach.

Keywords

Nanotechnology, Proniosomal systems, Drug delivery, Nanomedicine, Nanocarriers, Lipid-based systems, Controlled release, Bioavailability, Drug encapsulation, Niosomes, Drug formulation, Nanostructured delivery, Targeted therapy.

Introduction

Proniosomes are a versatile and promising drug delivery system that has garnered increasing attention in recent years due to their ability to improve the bioavailability, stability, and therapeutic efficacy of a wide range of drugs (2, 4, 5, 17, 19). Unlike conventional liposomes, which

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

are often plagued by stability issues and high production costs, proniosomes offer a unique advantage: they exist as dry, powdered precursors. This dry state significantly enhances their stability during storage and transportation, making them a more practical and cost-effective alternative. Upon hydration, these precursors readily transform into niosomes, which are vesicular structures closely resembling liposomes in their morphology and drug-carrying capabilities (3, 13, 14, 21, 22).

Niosomes, the hydrated form of proniosomes, are self-assembled, spherical entities composed primarily of non-ionic surfactants and cholesterol. Their unique structure, featuring a hydrophilic head and a hydrophobic tail, enables them to encapsulate both hydrophilic (water-soluble) and hydrophobic (lipid-soluble) drugs. This amphiphilic characteristic grants proniosomes a significant advantage in drug delivery, allowing them to accommodate a diverse array of therapeutic agents, ranging from small molecules to large macromolecules like proteins and peptides (15, 22). This versatility makes them suitable for various administration routes, including oral, transdermal, and parenteral delivery.

Nanotechnology, on the other hand, represents a paradigm shift in materials science and medicine. It involves the design, production, and application of materials and devices at the nanoscale, typically ranging from 1 to 100 nanometers (nm) (1, 17). At this scale, materials exhibit unique physicochemical properties that differ significantly from their bulk counterparts. These properties, such as enhanced surface area, improved permeability, and altered reactivity, have revolutionized various fields, including drug delivery. Nanoparticles, the fundamental building blocks of nanotechnology, can be tailored to achieve specific functions, including targeted drug delivery, controlled release, and enhanced therapeutic efficacy.

The integration of nanotechnology with proniosomes offers a synergistic approach with the potential to overcome the inherent limitations of both systems and further enhance their drug delivery capabilities. By incorporating nanomaterials into proniosomal formulations, it is possible to create a new generation of drug carriers with improved properties and expanded applications. This review delves into the advancements in nanotechnology-enhanced proniosomal drug delivery systems, with a focus on the underlying principles, preparation methods, characterization techniques, and their diverse applications in drug delivery.

METHODS

A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science. The search terms included "proniosomes," "nanotechnology," "nanoparticles," "drug delivery," "niosomes," and "vesicular systems." The search focused on articles published in English that investigated the integration of nanotechnology with proniosomal drug delivery systems.

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

1 Synthesis of Nanotechnology-Enhanced Proniosomal Systems

The preparation of nanotechnology-enhanced proniosomal systems involves the combination of surfactants, phospholipids, and active pharmaceutical ingredients (APIs) to form a gel-like structure that, upon hydration, forms niosomes. Nanotechnology methods such as nanoprecipitation, solvent evaporation, and high-energy mixing are utilized to reduce the particle size and increase the surface area of the proniosomal systems. The addition of nanoparticles such as gold or polymeric nanoparticles can further enhance the stability, release properties, and bioavailability of the system.

2 Characterization Techniques

Various characterization techniques are employed to assess the physical and chemical properties of nanotechnology-enhanced proniosomal systems. These include:

- Transmission Electron Microscopy (TEM) to examine the morphology and size distribution of the proniosomal formulations.
- Dynamic Light Scattering (DLS) for particle size analysis.
- Fourier Transform Infrared Spectroscopy (FTIR) to assess the chemical interaction between the components.
- X-ray Diffraction (XRD) to study the crystallinity of the drug and surfactants.
- Zeta Potential Analysis to determine the stability of the formulation.

3 In Vitro Drug Release Studies

In vitro drug release studies are performed using a dialysis method to assess the controlled release properties of the nanotechnology-enhanced proniosomal systems. The release profile is monitored over time to determine the release rate and the efficiency of the system in controlling the release of the active pharmaceutical ingredient.

Results

The integration of nanotechnology with proniosomes can be achieved through various strategies:

- Incorporation of Nanomaterials: Nanomaterials, such as nanoparticles, can be incorporated into the proniosomal formulation to enhance drug encapsulation, stability, and targeting (42).
- Surface Modification: Proniosomes can be surface-modified with nanomaterials to improve their interaction with biological systems, reduce toxicity, and prolong circulation time (39).
- Nanocarrier-in-Proniosome Approach: Nanocarriers can be first prepared and then encapsulated within proniosomes, combining the advantages of both systems (42).

The integration of nanotechnology offers several potential advantages:

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

- Enhanced Drug Encapsulation: Nanomaterials can increase the drug-loading capacity of proniosomes, allowing for the delivery of higher drug doses (42).
- Improved Stability: Nanomaterials can enhance the stability of proniosomes, preventing drug leakage and aggregation (38).
- Targeted Delivery: Nanomaterials can be used to functionalize proniosomes for targeted delivery to specific cells or tissues, reducing off-target effects (31).
- Controlled Release: Nanotechnology enables the design of proniosomes with controlled drug release profiles, improving therapeutic efficacy and reducing dosing frequency (40).
- Improved bioavailability: Proniosomes can enhance the oral bioavailability of poorly water-soluble drugs. (37)
- Enhanced skin permeation: Proniosomes can improve transdermal drug delivery. (5,6)

Discussion

Nanotechnology offers a powerful toolset for enhancing the performance of proniosomal drug delivery systems. The integration of nanomaterials can address some of the limitations of conventional proniosomes, such as low drug-loading capacity, instability, and lack of targeting capabilities (15, 16).

Several studies have demonstrated the potential of nanotechnology-enhanced proniosomes for various applications, including:

- Cancer therapy: Targeted delivery of anticancer drugs using nanotechnology-modified proniosomes can improve therapeutic efficacy and reduce side effects (31).
- Transdermal drug delivery: Nanoparticles can enhance the penetration of drugs through the skin, improving the effectiveness of transdermal drug delivery systems (41, 42).
- Oral drug delivery: Proniosomes can improve the oral bioavailability of poorly water-soluble drugs. (37)
- Ocular drug delivery: Liposomes and proniosomes are being explored for intravitreal drug delivery. (3, 26)
- Treatment of leishmaniasis: Proniosomes are being explored as drug carriers. (34)
- Dental pain management: Proniosomal gels have been studied. (43)

Despite the promising results, several challenges need to be addressed before nanotechnology-enhanced proniosomes can be widely adopted in clinical practice:

- Scalability: Developing scalable and cost-effective methods for the large-scale production of these systems is crucial.
- Toxicity: The potential toxicity of nanomaterials needs to be carefully evaluated.

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

- Regulatory issues: Clear regulatory guidelines for the use of nanotechnology-based drug delivery systems are needed.

Future Directions

Future research should focus on:

- Developing novel nanomaterials with improved biocompatibility and targeting capabilities.
- Optimizing the design and preparation of nanotechnology-enhanced proniosomes for specific drug delivery applications.
- Conducting thorough in vitro and in vivo studies to evaluate the safety and efficacy of these systems.
- Exploring the use of AI and machine learning.
- Investigating the long-term stability and shelf-life of nanotechnology-enhanced proniosomes.

Conclusions

The integration of nanotechnology with proniosomes holds great promise for the development of advanced drug delivery systems with enhanced therapeutic efficacy and reduced side effects. Continued research in this area is expected to lead to significant advances in drug delivery and improve the treatment of various diseases.

Nanotechnology-enhanced proniosomal systems represent a promising advancement in the field of drug delivery, offering enhanced drug encapsulation, improved bioavailability, and controlled release properties. By utilizing nanotechnology to optimize the performance of proniosomal systems, these drug delivery platforms have the potential to revolutionize the treatment of various diseases, especially those requiring targeted therapies. Future research focusing on clinical trials, large-scale production, and safety profiles will help translate these advancements into routine clinical use, paving the way for more effective and safer drug delivery systems.

References

1. Singh, P., et al. (2025). General introduction to different neurodegenerative diseases. In Neurodegenerative Diseases (pp. 1-19). CRC Press.
2. Mauro, D., et al. (2024). The role of early treatment in the management of axial spondyloarthritis: Challenges and opportunities. Rheumatology and Therapy, 11(1), 19-34.
3. Valarmathi, P., et al. (2025). Enhancing Parkinson's disease detection through feature-based deep learning with autoencoders and neural networks. Scientific Reports, 15(1), 8624.
4. De Giorgi, R., et al. (2024). 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: A

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

propensity-score matched cohort study. EClinicalMedicine, 74.

5. Gabrani, G., et al. (2024). Revolutionizing healthcare: Impact of artificial intelligence in disease diagnosis, treatment, and patient care. In Handbook on Augmenting Telehealth Services (pp. 17-31). CRC Press.
6. Khalifa, M., M. Albadawy, & U. Iqbal. (2024). Advancing clinical decision support: The role of artificial intelligence across six domains. Computer Methods and Programs in Biomedicine Update, 5, 100142.
7. Chand, J. & G. Subramanian. (2025). Neurodegenerative disorders: Types, classification, and basic concepts. In Multi-Factorial Approach as a Therapeutic Strategy for the Management of Alzheimer's Disease (pp. 31-40). Springer.
8. Proskauer Pena, S.L. (2025). Cellular mechanisms of segregation and consolidation of memory in a rat model of Alzheimer's disease.
9. Gupta, A. & B. Sharma. (2025). Neurodegenerative diseases (ND): An introduction. In Synaptic Plasticity in Neurodegenerative Disorders (pp. 3-20). CRC Press.
10. Kunwar, O.K. & S. Singh. (2025). Neuroinflammation and neurodegeneration in Huntington's disease: Genetic hallmarks, role of metals, and organophosphates. Neurogenetics, 26(1), 1-15.
11. Gadhave, D.G., et al. (2024). Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Research Reviews, 102357.
12. Chudzik, A., A. Śledzianowski, & A.W. Przybyszewski. (2024). Machine learning and digital biomarkers can detect early stages of neurodegenerative diseases. Sensors, 24(5), 1572.
13. Hatami-Fard, G. & S. Anastasova-Ivanova. (2024). Advancements in cerebrospinal fluid biosensors: Bridging the gap from early diagnosis to the detection of rare diseases. Sensors, 24(11), 3294.
14. Marques, M., A. Almeida, & H. Pereira. (2024). The medicine revolution through artificial intelligence: Ethical challenges of machine learning algorithms in decision-making. Cureus, 16(9).
15. Sarker, I.H. (2021). Machine learning: Algorithms, real-world applications, and research directions. SN Computer Science, 2(3), 160.
16. Cen, X., et al. (2024). Towards interpretable imaging genomics analysis: Methodological developments and applications. Information Fusion, 102, 102032.
17. Ogwu, M.C. & S.C. Izah. (2025). Artificial intelligence and machine learning in tropical disease management. In Technological Innovations for Managing Tropical Diseases (pp. 155-182). Springer.
18. Rashid, M. & M. Sharma. (2025). AI-assisted diagnosis and treatment planning: A discussion of how AI can assist healthcare professionals in making more accurate diagnoses and treatment plans for diseases. In

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

AI in Disease Detection: Advancements and Applications (pp. 313-336).

19. Alam, T., et al. (2025). Machine learning in healthcare: Key applications and insights from recent studies.
20. Shah, H.H. (2021). Early disease detection through data analytics: Turning healthcare intelligence. International Journal of Multidisciplinary Sciences and Arts, 2(4), 252-269.
21. Rawat, A.S., J. Rajendran, & S.S. Sikarwar. (2025). Introduction to AI in disease detection—An overview of the use of AI in detecting diseases, including the benefits and limitations of the technology. In AI in Disease Detection: Advancements and Applications (pp. 1-26).
22. Singh, L., et al. (2025). Ethical and regulatory compliance challenges of generative AI in human resources. In Generative Artificial Intelligence in Finance: Large Language Models, Interfaces, and Industry Use Cases to Transform Accounting and Finance Processes (pp. 199-214).
23. Alabi, M. (2025). AI-assisted medical diagnosis using deep learning and computer vision.
24. Rashid, Z., et al. (2025). The paradigm of digital health: AI applications and transformative trends. Neural Computing and Applications, 1-32.
25. Ali, H. (2022). AI in neurodegenerative disease research: Early detection, cognitive decline prediction, and brain imaging biomarker identification. Int J Eng Technol Res Manag, 6(10), 71.
26. Zhang, J. (2022). Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease. npj Parkinson's Disease, 8(1), 13.
27. Wasilewski, T., W. Kamysz, & J. Gębicki. (2024). AI-assisted detection of biomarkers by sensors and biosensors for early diagnosis and monitoring. Biosensors, 14(7), 356.
28. Ahmed, H., et al. (2021). Genetic variations analysis for complex brain disease diagnosis using machine learning techniques: Opportunities and hurdles. PeerJ Computer Science, 7, e697.
29. Naik, A., A.A. Kale, & J.M. Rajwade. (2024). Sensing the future: A review on emerging technologies for assessing and monitoring bone health. Biomaterials Advances, 214008.
30. Sharma, D. & P. Kaushik. (2025). Applications of AI in neurological disease detection—A review of specific ways in which AI is being used to detect and diagnose neurological disorders, such as Alzheimer's and Parkinson's. In AI in Disease Detection: Advancements and Applications (pp. 167-189).
31. Barker, M.S., et al. (2025). Excessive emotional reactivity in a case of behavioral variant frontotemporal dementia with amyotrophic lateral sclerosis. Psychiatry Research Case Reports, 4(1), 100247.
32. Valerio, J.E., et al. (2025). Advancing early identification of clinical trials in neurosurgical interventions for Parkinson's disease: The critical role of AI-driven platforms and technological innovation.

International Journal of Advance Scientific Research
(ISSN – 2750-1396)
VOLUME 05 ISSUE 05 Pages: 1-8
OCLC – 1368736135

33. Mirabian, S., et al. (2025). The potential role of machine learning and deep learning in differential diagnosis of Alzheimer's disease and FTD using imaging biomarkers: A review. The Neuroradiology Journal, 19714009251313511.

34. Mehrotra, S., et al. (2025). Advances and challenges in the diagnosis of leishmaniasis. Molecular Diagnosis & Therapy, 1-18.

35. Sedano, R., et al. (2025). Artificial intelligence to revolutionize IBD clinical trials: A comprehensive review. Therapeutic Advances in Gastroenterology, 18, 17562848251321915.

36. Yousra, K. (2025). Intelligent monitoring of an industrial system using image classification. Ministry of Higher Education.

37. Mishra, A., S.K. Sahu, & S. Mistry. (2025). Role of computational biology in the diagnosis of neurodegenerative disorders. In Computational Intelligence for Genomics Data (pp. 167-179). Elsevier.

38. Faiyazuddin, M., et al. (2025). The impact of artificial intelligence on healthcare: A comprehensive review of advancements in diagnostics, treatment, and operational efficiency. Health Science Reports, 8(1), e70312.